EFFECTS OF PERINDOPRIL, TELMISARTAN, AND THEIR COMBINATIONS ON CLINICAL, FUNCTIONAL, AND OXIDATIVE STRESS PARAMETERS IN PATIENTS WITH CHRONIC HEART FAILURE AND TYPE 2 DIABETES MELLITUS

1. 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation // Circulation 2009;119; e391-e479.

2. American Diabetes Association – Standards of Medical Care in Diabetes 2009// Diabetes Care 2009; 32(1): S13-S61.

3. Dzau V., Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement // Am Heart J. 1991; 121(4 Pt 1):1244-63.

4. Соловьева Э. Ю., Миронова О. П., Баранова О. А. и др. Свободнорадикальные процессы и антиоксидантная терапия при ишемии головного мозга // Журнал неврологии и психиатрии им. С.С. Корсакова, 2008; 6: 245-260.

5. Dzau V.J., Antman E.M., Black H.R. et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease)// Circulation 2006; 114(25):2850-70.

6. Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure // J Clin Invest, 2005; 115: 500–508.

7. Schraufstatter I.U., Hyslop P.A., Jackson J. et al. Oxidant injury of cell // Int J Tissue React, 1987; 9 (4): 317-324.

8. Escargueil-Blanc I, Meilhac O, Pieraggi MT. Oxidized LDLs induce massive apoptosis of cultured human endothelial cells trough a calcium-depended pathway. Prevention by aurintricarboxylic acid.// Tromb Vasc Biol, 1997; 17 (2): 331-339.

9. Landmesser U., Spiekermann S., Dikalov S. et al. Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase// Circulation, 2002; 106: 3073–3078.

10. Грызунов Ю.А., Добрецов Г.Е. Альбумин сыворотки крови в клинической медицине. М: ГЭОТАР, 1998.

11. Иванов С.Г., Ситникова М.Ю., Шляхто Е.В. Роль оксидативного стресса в развитии и прогрессировании хронической сердечной недостаточности: актуальность и возможность его коррекции// Кардиология СНГ, 2006; 4: 267-270.

12. Berlett B.S., Stadtman E.R. Protein oxidation in aging, disease, and oxidative stress// J Biol Chem, 1997; 272: 20313–20316.

13. Dalle-Donnea I., Rossib R., Giustarinib D. et al. Protein carbonyl groups as biomarkers of oxidative stress// Clinica Chimica Acta, 2003; 329: 23–38.

14. Banfi C, Brioschi M, Barcella S, et al. Oxidized proteins in plasma of patients with heart failure: Role in endothelial damage// Eur. J. Heart Failure, 2008; 10(3): 244-251.

15. McMurray J, Chopra M, Abdullah I, Smith WE, Dargie HJ. Evidence of oxidative stress in chronic heart failure in humans// Eur Heart J, 1993; 14: 1493–1498.

16. Фёдорова Т.Н. Окислительный стресс и защита головного мозга от ишемического повреждения. Диссерт. …докт. медицинских наук, 2004.

17. Ball AM, Sole MJ. Oxidative stress and the pathogenesis of heart failure// Cardio Clin. 1998; 16 (7): 665-675.

18. Benson SC., Pershadsingh HA., Ho CI et al. Identification of Telmisartan as a Unique Angiotensin II Receptor Antagonist with Selective PPAR-γ Modulating Activity// Hypertension 2004; 43:993-1002.

19. Duan SZ., Usher MG., Mortensen NM. Peroxisome Proliferator-Activated Receptor-γ Mediated Effects in the Vasculature// Circulation Research 2008; 102:283-294.

20. Qingping Tian, Ryohei Miyazaki, Toshihiro Ichiki et al. Inhibition of Tumor Necrosis Factor-α-Induced IL-6 Expression by Telmisartan Through Cross-talk of Peroxisome Proliferator-Activated Receptor-γ with Nuclear Factor κβ and CCAAT/Enhancer Binding Protein β// Hypertension 2009; 53:798-804.